189 related articles for article (PubMed ID: 20401461)
1. Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient mice.
Duan SZ; Usher MG; Foley EL; Milstone DS; Brosius FC; Mortensen RM
Diabetologia; 2010 Jul; 53(7):1493-505. PubMed ID: 20401461
[TBL] [Abstract][Full Text] [Related]
2. Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones.
Lu M; Sarruf DA; Talukdar S; Sharma S; Li P; Bandyopadhyay G; Nalbandian S; Fan W; Gayen JR; Mahata SK; Webster NJ; Schwartz MW; Olefsky JM
Nat Med; 2011 May; 17(5):618-22. PubMed ID: 21532596
[TBL] [Abstract][Full Text] [Related]
3. Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism.
Dallaire P; Bellmann K; Laplante M; Gélinas S; Centeno-Baez C; Penfornis P; Peyot ML; Latour MG; Lamontagne J; Trujillo ME; Scherer PE; Prentki M; Deshaies Y; Marette A
Diabetes; 2008 Aug; 57(8):1999-2011. PubMed ID: 18458147
[TBL] [Abstract][Full Text] [Related]
4. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice.
Duan SZ; Ivashchenko CY; Russell MW; Milstone DS; Mortensen RM
Circ Res; 2005 Aug; 97(4):372-9. PubMed ID: 16051889
[TBL] [Abstract][Full Text] [Related]
5. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.
Gavrilova O; Haluzik M; Matsusue K; Cutson JJ; Johnson L; Dietz KR; Nicol CJ; Vinson C; Gonzalez FJ; Reitman ML
J Biol Chem; 2003 Sep; 278(36):34268-76. PubMed ID: 12805374
[TBL] [Abstract][Full Text] [Related]
6. Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice.
Barbieri M; Di Filippo C; Esposito A; Marfella R; Rizzo MR; D'Amico M; Ferraraccio F; Di Ronza C; Duan SZ; Mortensen RM; Rossi F; Paolisso G
PLoS One; 2012; 7(4):e35999. PubMed ID: 22563432
[TBL] [Abstract][Full Text] [Related]
7. Activation of peroxisome proliferator-activated receptor-γ by rosiglitazone improves lipid homeostasis at the adipose tissue-liver axis in ethanol-fed mice.
Sun X; Tang Y; Tan X; Li Q; Zhong W; Sun X; Jia W; McClain CJ; Zhou Z
Am J Physiol Gastrointest Liver Physiol; 2012 Mar; 302(5):G548-57. PubMed ID: 22173916
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone inhibits expression and secretion of PEDF in adipose tissue and liver of male SD rats via a PPAR-γ independent mechanism.
Yang S; Luo T; Zhou H; Lv Q; Liu L; Zhang W; Gao R; Chen S; Xia W; Luo M; Cheng Q; Li Q
Endocrinology; 2014 Mar; 155(3):941-50. PubMed ID: 24424059
[TBL] [Abstract][Full Text] [Related]
9. Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model.
Kim HJ; Jung TW; Kang ES; Kim DJ; Ahn CW; Lee KW; Lee HC; Cha BS
Metabolism; 2007 May; 56(5):676-85. PubMed ID: 17445544
[TBL] [Abstract][Full Text] [Related]
10. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination.
Tsuchida A; Yamauchi T; Takekawa S; Hada Y; Ito Y; Maki T; Kadowaki T
Diabetes; 2005 Dec; 54(12):3358-70. PubMed ID: 16306350
[TBL] [Abstract][Full Text] [Related]
12. CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo.
Ming Y; Hu X; Song Y; Liu Z; Li J; Gao R; Zhang Y; Mei H; Guo T; Xiao L; Wang B; Wu C; Xiao X
PLoS One; 2014; 9(7):e102102. PubMed ID: 25004107
[TBL] [Abstract][Full Text] [Related]
13. Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance.
Lessard SJ; Rivas DA; Chen ZP; Bonen A; Febbraio MA; Reeder DW; Kemp BE; Yaspelkis BB; Hawley JA
Diabetes; 2007 Jul; 56(7):1856-64. PubMed ID: 17440174
[TBL] [Abstract][Full Text] [Related]
14. Impact of increased PPARgamma activity in adipocytes in vivo on adiposity, insulin sensitivity and the effects of rosiglitazone treatment.
Takasawa K; Kubota N; Terauchi Y; Kadowaki T
Endocr J; 2008 Aug; 55(4):767-76. PubMed ID: 18506083
[TBL] [Abstract][Full Text] [Related]
15. Role and mechanism of rosiglitazone on the impairment of insulin secretion induced by free fatty acids on isolated rat islets.
Tian JY; Li G; Gu YY; Zhang HL; Zhou WZ; Wang X; Zhu HD; Luo TH; Luo M
Chin Med J (Engl); 2006 Apr; 119(7):574-80. PubMed ID: 16620699
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma activation promotes infiltration of alternatively activated macrophages into adipose tissue.
Stienstra R; Duval C; Keshtkar S; van der Laak J; Kersten S; Müller M
J Biol Chem; 2008 Aug; 283(33):22620-7. PubMed ID: 18541527
[TBL] [Abstract][Full Text] [Related]
17. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus.
Mensink M; Hesselink MK; Russell AP; Schaart G; Sels JP; Schrauwen P
Int J Obes (Lond); 2007 Aug; 31(8):1302-10. PubMed ID: 17310221
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion.
Lupi R; Del Guerra S; Marselli L; Bugliani M; Boggi U; Mosca F; Marchetti P; Del Prato S
Am J Physiol Endocrinol Metab; 2004 Apr; 286(4):E560-7. PubMed ID: 14625208
[TBL] [Abstract][Full Text] [Related]
19. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.
Tiikkainen M; Häkkinen AM; Korsheninnikova E; Nyman T; Mäkimattila S; Yki-Järvinen H
Diabetes; 2004 Aug; 53(8):2169-76. PubMed ID: 15277403
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet.
Matsui J; Terauchi Y; Kubota N; Takamoto I; Eto K; Yamashita T; Komeda K; Yamauchi T; Kamon J; Kita S; Noda M; Kadowaki T
Diabetes; 2004 Nov; 53(11):2844-54. PubMed ID: 15504964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
